PIK3CA and breast cancer: Moreover, pre-clinical data are implicating mTORC signaling in resistance to PI3K inhibitors: PIK3CA-mutant breast cancer models resistant to PI3K inhibitors have been shown to exhibit sustained mTORC1 signaling29, and treatment with a rapalog was sufficient to sensitize resistant cells to PI3Kα inhibitor alpelisib29.